NextCure, Inc. (NXTC): Cash & Equivalents
$25.98M
As of 2025-12-31
$15.26M
As of 2026-06-30
-0.8%
3-year compound annual growth
-4.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.98M | -6.3% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $27.73M | +111.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $13.08M | -50.9% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $26.63M | +115.9% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $12.34M | -62.4% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $32.77M | -3.9% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $34.09M | -74.8% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $135.17M | n/a | 2020-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| NextCure, Inc. (NXTC) | 2025-12-31 | $25.98M | -6.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $45.09M | +48.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $29.20M | +11.7% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $6.44M | +203.7% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $48.00M | -34.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $0 | n/a |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $41.30M | -41.9% |
Compare NXTC, IRD, COYA, UNCY side by side · Screen every company in Pharmaceutical Preparations ↗